|

Albumin Paclitaxel Clinical Trials

8 actively recruiting trials

Also known as: nab-paclitaxel

Pipeline

Phase 1: 1Phase 2: 5Phase 2/3: 1

Top Sponsors

  • Henan Cancer Hospital2
  • Weijia Fang, MD1
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
  • Shanghai Jiao Tong University School of Medicine1
  • Peking University Cancer Hospital & Institute1

Indications

  • Cancer8
  • Oral Squamous Cell Carcinoma2
  • Breast Cancer2
  • Immunotherapy Esophagus Cancer1
  • Anti-PD-11

Other8 trials

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Phase 1
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Phase 2
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Phase 2/3
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Phase 2
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Phase 2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.